로킷헬스케어

376900KOSDAQSector: Pharma & Biotech

₩53,100▼ 13.52%Market cap ₩842.9BAs of Jul 21, 2026 close · updated once daily

Grade C44.9 ptsTop 62% of 2,523 stocks

Financial strength

31.7

Growth momentum

88.9

Price attractiveness

28.5

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

31.7

How much debt does it carry relative to equity?

Debt-to-equity ratio

376.3%

✗ Below median · Top 95.7% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

129.3%

✗ Below median · Top 64.4% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

1.7%

✓ Above median · Top 42.6% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-24.6%

✗ Below median · Top 70.5% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

88.9

How much did revenue grow in a year?

Revenue growth (YoY)

100.2%

✓ Above median · Top 9.4% in sector

Sector median 6.4%

Did core profits grow in a year?

Operating income change (YoY)

108.1%

✓ Above median · Top 12.7% in sector

Sector median 3.6%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

28.5

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✓ Above median · Top 46.5% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

72.99x

✗ Below median · Top 96.5% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15